In the BioHarmony Drug Report Database

"Preview" Icon

Solriamfetol

Sunosi (solriamfetol) is a small molecule pharmaceutical. Solriamfetol was first approved as Sunosi on 2019-06-17. It is used to treat sleepiness in the USA. It has been approved in Europe to treat narcolepsy and obstructive sleep apnea. It is known to target sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. Sunosi’s patents are valid until 2040-03-19 (FDA).

 

Trade Name

 

Sunosi
 

Common Name

 

solriamfetol
 

ChEMBL ID

 

CHEMBL4297620
 

Indication

 

narcolepsy, obstructive sleep apnea, sleepiness
 

Drug Class

 

Norepinephrine–dopamine reuptake inhibitors

Image (chem structure or protein)

Solriamfetol structure rendering